June 25
- June 26
KCAS Bio is happy to announce our participation in the 13th edition of the Antibody Industrial Symposium (AIS), taking place in Tours, France. As a premier event in the antibody and therapeutic development sector, AIS offers a unique platform for scientific exchange, collaboration, and innovation. KCAS Bio’s Expertise…
Blogs
KCAS Bio participated in the AAPS National Biotechnology Conference (NBC), held from May 4 to May 7, 2025, in Boston. It was a productive event that allowed us to connect with sponsors, exchange ideas with peers, and present our latest work in bioanalytical science. Our experts…
Posters & Papers
Discover in this poster presented by Jessica Phan at WRIB 2025 on the “Development and Optimization of a Quantitative Assay for an Investigational Anti-Malarial Monoclonal Antibody Drug Candidate in Human Whole Blood Using Volumetric Absorptive Microsampling (VAMS)”. Quantitative Assay for an Investigational Anti-Malarial Monoclonal Antibody Drug Candidate |…
Webinars
As the field of biotherapeutics rapidly evolves, the development of advanced conjugated therapies such as Antibody-Drug Conjugates (ADCs), Antibody-RNA Conjugates (ARCs), siRNA/oligos, and antibody-peptide conjugates has gained significant momentum. These next-generation therapeutics offer promising efficacy and safety profiles for treating various conditions, including cancer, rare diseases, and in vaccine development.
Blogs
ADCs represent a promising class of targeted therapies, and understanding the intricacies of their analysis is crucial for their successful development. In this blog, we address common questions to guide you through the various considerations involved in ADC research and testing. We will cover key topics related to the…
Blogs
Antibody drug conjugates (ADCs) are important targeted therapies in oncology. These are complex moieties consisting of a cell-targeting antibody combined with an active payload through a chemical linker. Key Components to Monitor in PK Studies Two significant components to monitor for PK studies are the (1) intact antibody drug conjugate…
Podcasts
In episode 84 of “The Weekly Bioanalysis”, our special guest, Bryan Parmentier, joins Dom and John to discuss his background and current role at KCAS Bio, offering insights into the field of small molecule method development. He delves into the typical challenges encountered when working with LC-MS analytes, and how…
December 10
- December 10
KCAS Bio is excited to sponsor the upcoming Pharmaceutical & BioScience Society (PBSS) workshop “Antibody-Drug Conjugates from Discovery to Development: Chemistry, Engineering, Characterization, CMC, PK/Tox, Clinical Design and Intellectual Property,” on December 10th from 8:45am – 5:30pm PST in San Diego, California at the Hyatt Regency – La Jolla. Showcasing…
Blogs
In the complex and dynamic bioanalytical landscape of antibody-drug conjugate (ADC) services, where often time is critical and every research dollar counts, hybrid technology is quickly emerging as a game-changer. Hybrid offers a spectrum of advantages that redefine traditional approaches to bioanalytical ADC drug development. At the forefront of these…
Blogs
If you are part of the Biotech/Pharma community, you may be familiar with the (J.P. Morgan) JPM Healthcare Conference that takes place annually in January and typically in San Francisco. This was the 42nd Annual JPM Healthcare Conference and it is the world’s largest healthcare symposium. This year the mood…
Podcasts
Starting with a description of Antibody Drug Conjugates (or ADCs, for short), Dom and John dive into this field of the industry and discuss the ways these services have changed over time and even how they’ve changed recently. They review the role of ADCs in meeting some of…